Teva Pharmaceutical Industries Chief Medical Officer Eric Hughes to Depart

MT Newswires Live11-19 06:42

Teva Pharmaceutical Industries (TEVA) said Eric Hughes, chief medical officer and executive vice president of global research and development, is departing after accepting a position outside the company.

Hughes will remain with Teva through the coming months to support a transition, the company said Wednesday. David Gardiner, head of innovative medicines and clinical development, will serve as R&D transition lead until a permanent successor is named.

Teva said its strategy, R&D priorities and expectations remain unchanged and that it has begun a search for a permanent successor.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment